AACR 2021 | ZENITH20-5: poziotinib for EGFR/HER2 exon 20 mutant NSCLC
Xiuning Le, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the findings of the Phase II ZENITH20-5 trial (NCT03318939) investigating poziotinib in patients with EGFR or HER2 exon 20 mutant non-small cell lung cancer (NSCLC). Poziotinib is a tyrosine kinase inhibitor which targets these exon 20 mutations. Preliminary results of the ZENITH20-5 trial have demonstrated that poziotinib administered twice daily improves safety and tolerability in this cohort of patients. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Xiuning Le, MD, PhD, has received consulting/advisory fees from EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Eli Lilly, Boehringer Ingelheim, Bristol-Myers Squibb and Celgene; and has received research funding from Eli Lilly and Boehringer Ingelheim.
